BridgeBio Pharma Total Liabilities and Share Holders Equity 2018-2024 | BBIO

BridgeBio Pharma total liabilities and share holders equity for the quarter ending June 30, 2024 was $0.794B, a 57.72% increase year-over-year.

  • BridgeBio Pharma total liabilities and share holders equity for 2023 was $0.546B, a 12.3% decline from 2022.
  • BridgeBio Pharma total liabilities and share holders equity for 2022 was $0.623B, a 38.48% decline from 2021.
  • BridgeBio Pharma total liabilities and share holders equity for 2021 was $1.013B, a 43.95% increase from 2020.

BridgeBio Pharma Total Liabilities and Share Holders Equity 2018-2024 | BBIO

  • BridgeBio Pharma total liabilities and share holders equity for 2023 was $0.546B, a 12.3% decline from 2022.
  • BridgeBio Pharma total liabilities and share holders equity for 2022 was $0.623B, a 38.48% decline from 2021.
  • BridgeBio Pharma total liabilities and share holders equity for 2021 was $1.013B, a 43.95% increase from 2020.
Related Stocks
Company NameMarket
Cap
Teva Pharmaceutical Industries (TEVA)$20.1B
Dr Reddy's Laboratories (RDY)$13.1B
Bausch Health Cos (BHC)$3B
Amphastar Pharmaceuticals (AMPH)$2.4B
Supernus Pharmaceuticals (SUPN)$1.8B
Taysha Gene Therapies (TSHA)$449M
Personalis (PSNL)$315M
Assembly Biosciences (ASMB)$117M
Acasti Pharma (ACST)$28M
Sol-Gel Technologies (SLGL)$20M
Evoke Pharma (EVOK)$4M
Teligent (TLGT)$0M